Q-linea (QLINEA.ST) Stock Analysis & AI Equity Report
Q-linea (QLINEA.ST) overview
Q-linea (QLINEA.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Q-linea reported revenue of SEK 11.1m and operating profit of SEK -180m; the year-end share price was 24.94 SEK and market capitalisation was SEK 166m. Q-linea is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Q-linea's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Q-linea
Q-linea AB is a Swedish medical technology company that develops and commercialises diagnostic systems for severe infectious diseases. Its ASTar platform provides rapid antibiotic susceptibility testing from positive blood cultures, supported by consumables, software and related services. The company’s products are aimed at shortening time to targeted treatment and helping laboratories manage antimicrobial resistance.
Generate the Q-linea report
Q-linea is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Q-linea and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.